

Next Generation Sequencing for Cancer

MEDICAL POLICY NUMBER: 352

|                            |   |    |
|----------------------------|---|----|
| Effective Date: 1/1/2026   | COVERAGE CRITERIA .....                       | 2  |
| Last Review Date: 12/2025  | POLICY CROSS REFERENCES.....                  | 3  |
| Next Annual Review: 5/2026 | POLICY GUIDELINES.....                        | 3  |
|                            | REGULATORY STATUS.....                        | 4  |
|                            | CLINICAL EVIDENCE AND LITERATURE REVIEW ..... | 5  |
|                            | HEALTH EQUITY CONSIDERATIONS .....            | 6  |
|                            | BILLING GUIDELINES AND CODING .....           | 7  |
|                            | REFERENCES.....                               | 12 |
|                            | POLICY REVISION HISTORY.....                  | 12 |

**INSTRUCTIONS FOR USE:** Company Medical Policies serve as guidance for the administration of plan benefits. Medical policies do not constitute medical advice nor a guarantee of coverage. Company Medical Policies are reviewed annually and are based upon published, peer-reviewed scientific evidence and evidence-based clinical practice guidelines that are available as of the last policy update. The Company reserves the right to determine the application of medical policies and make revisions to medical policies at any time. The scope and availability of all plan benefits are determined in accordance with the applicable coverage agreement. Any conflict or variance between the terms of the coverage agreement and Company Medical Policy will be resolved in favor of the coverage agreement. Coverage decisions are made on the basis of individualized determinations of medical necessity and the experimental or investigational character of the treatment in the individual case. In cases where medical necessity is not established by policy for specific treatment modalities, evidence not previously considered regarding the efficacy of the modality that is presented shall be given consideration to determine if the policy represents current standards of care.

**SCOPE:** Providence Health Plan, Providence Health Assurance, and Providence Plan Partners as applicable (referred to individually as “Company” and collectively as “Companies”).

## PLAN PRODUCT AND BENEFIT APPLICATION

☒ Commercial

☐ Medicaid/OHP\*

☐ Medicare\*\*

### \*Medicaid/OHP Members

*Oregon:* Services requested for Oregon Health Plan (OHP) members follow the OHP Prioritized List and Oregon Administrative Rules (OARs) as the primary resource for coverage determinations. Medical policy criteria below may be applied when there are no criteria available in the OARs and the OHP Prioritized List.

Medicaid must also meet the genetic testing criteria governed by the Oregon Health Plan (OHP) Prioritized List of Health Services and the OHP Diagnostic Procedure Codes / Procedure Group 1119.  
<https://www.oregon.gov/oha/HPA/DSI-HERC/Pages/Prioritized-L>

### \*\*Medicare Members

This Company policy may be applied to Medicare Plan members only when directed by a separate Medicare policy. Note that investigational services are considered “**not medically necessary**” for Medicare members.

## COVERAGE CRITERIA

Note: This policy does not address circulating tumor cell/cell-free DNA testing.

- I. Multi-gene or next generation sequencing (NGS) panels may be considered **medically necessary** in members with somatic cancer when all of the following criteria are met (A.-F.):
  - A. Member has **one** of the following conditions (1.-2.):
    1. Recurrent, relapsed, metastatic, or advanced (stage III or IV) solid tumor; **or**
    2. Risk assessment using broad molecular testing has been validated by the [National Comprehensive Cancer Network \(NCCN\) guidelines](#) as a category 1 or 2A recommendation for the member’s cancer type (see [Policy Guidelines](#) section for utilizing NCCN guidelines); **and**
  - B. **One or more** of the following is true (1.-2.):
    1. Genomic biomarker-linked therapies have been approved by the Food and Drug Administration (FDA) for the specific cancer/disease site; **or**
    2. Treatment is being considered for which there are specific genomic biomarker-based contraindications or exclusions; **and**
  - C. Member has not been previously tested with a multi-gene panel on the same tumor sample for the same indication; **and**
  - D. Results of testing will directly impact clinical decision making, including both of the

following clinical notes (1.-2.):

1. Reason (indication) for performing test, including tumor type; **and**
  2. How results from current test request will impact clinical decision making; **and**
- E. Testing is being conducted in a Clinical Laboratory Improvement Amendments (CLIA)-certified lab; **and**
- F. Documentation states that member has decided to seek further cancer treatment.
- II. Repeat testing may be considered **medically necessary** in the event of tumor progression after initial response to a targeted therapy with a known genetic-driven resistance mechanism.
- III. Testing of multiple concurrent tumors may be considered **medically necessary** when there is clinical documentation of separate, synchronous tumors or clinical presentation supports the potential for two independent primary tumors.
- IV. Multi-gene panels/NGS panels to assess mismatch repair deficiency status (dMMR), microsatellite instability-high status (MSI-H), and/or tumor mutational burden (TMB) may be considered **medically necessary** in members with advanced or metastatic solid tumors who are candidates for immunotherapy.
- V. Multi-gene panels/NGS panels are considered **not medically necessary** when criteria above are not met.

Link to [Evidence Summary](#)

## POLICY CROSS REFERENCES

- [Circulating Tumor Cell and DNA Assays for Cancer Management](#), MP122
- [Next Generation Sequencing for Minimal Residual Disease Detection](#), MP110
- [Genetic and Molecular Testing](#), MP215
- [Genetic Counseling](#), MP316

The full Company portfolio of current Medical Policies is available online and can be [accessed here](#).

## POLICY GUIDELINES

### DOCUMENTATION REQUIREMENTS

In order to determine the clinical utility of a genetic test, the following documentation must be provided at the time of the request. Failure to submit complete documentation may affect the outcome of the review.

- Specific gene, trade or proprietary name of the test, or if a custom-built test, include every gene(s) and/or component of the test
- Name of laboratory where the testing is being conducted or was conducted

- All relevant CPT/HCPCS codes billed

## RESOURCES

Examples of next generation sequencing (NGS) panels include but are not limited to:

- Aventa FusionPlus™, Aventa Genomics, LLC
- Cancer MI Tumor Seek, Caris Life Sciences
- MI Tumor Seek Hybrid, Caris Life Sciences
- FoundationOne CDx
- Genetrails Comprehensive Solid Tumor Panel
- Genetrails Hematologic Malignancies Panel
- ONCO/Reveal™ DX Lung and Colon Cancer Assay, Pillar® Biosciences
- ProvSeq 523/Providence Personalized Medicine Panel- Solid Tumor
- Tempus xT, Tempus
- Tempus xR, Tempus

## Resources

- National Comprehensive Cancer Network (NCCN) guidelines can be accessed on website at: [https://www.nccn.org/guidelines/category\\_1](https://www.nccn.org/guidelines/category_1)
- The internal resource for NCCN Guidelines is linked [here](#).

## BACKGROUNDS

### Multi-gene panel testing

Multi-gene panel testing refers to a laboratory test in which many genes are studied in a sample of tissue. In patients with cancer, multi-gene panels detect mutations and alterations in a broad selection of genes that may help plan treatment or predict prognosis.

### Next-Generation Sequencing (NGS)

Next generation sequencing (NGS), also known as massively parallel or deep sequencing, refers to a technology for determining the sequence of DNA or RNA to study genetic variations associated with disease or other biological phenomena.

## REGULATORY STATUS

### U.S. FOOD AND DRUG ADMINISTRATION (FDA)

Approval or clearance by the Food and Drug Administration (FDA) does not in itself establish medical necessity or serve as a basis for coverage. Therefore, this section is provided for informational purposes only.

## **CLINICAL EVIDENCE AND LITERATURE REVIEW**

### **EVIDENCE REVIEW**

In 2022, Hayes published a report on comprehensive molecular profiling tests for solid tumors intended to be used as a broad molecular profiling tool to assigned matched therapy.<sup>1</sup> The report reviewed abstracts of studies addressing comprehensive molecular profiling (CMP) test with > 50 genes, excluding CMP via liquid biopsy and targeted testing.

Based on a review of included abstracts, there appears to be some support—as indicated by the number of abstracts identified (12)—with regard to CMP tests for the intended use as a broad molecular profiling tool (assessing DNA or RNA variants in > 50 genes) to identify biomarkers present in solid tumor tissue and then assign matched therapy specific to those biomarkers (may include FDA-approved or off-label use), and reported outcomes of treatment and compared with patients who did not receive matched targeted treatment based on the results of the CMP test. This conclusion reflects:

- A moderate number of abstracts were identified that met inclusion criteria, though some of the abstracts are likely to have patient overlap or represent multiple publications from a single clinical trial.
- Abstracts reported the use of CMP testing for broad molecular profiling to guide treatment and impact patient outcomes (clinical utility).
- No abstracts within the search time frame (approximately 5 years) had a randomized controlled trial (RCT) design; however, 1 earlier RCT and 1 in progress trial were identified. Findings from these studies should be interpreted with caution. In general, these studies evaluated patients who underwent CMP and compared outcomes between those who received matched therapies based on the findings and those who did not receive matched therapies. Of note, patients who did not receive matched therapies may have had fewer treatment options or other disease-related factors that could complicate any conclusions drawn from this comparison.

### **CLINICAL PRACTICE GUIDELINES**

#### **American Society of Clinical Oncology**

In 2022, ASCO published a provisional clinical opinion on Somatic Genomic Testing in Patients with Metastatic or Advanced Cancer.<sup>2</sup> The publication recommended the following guidelines:

- “PCO 1.2.1. For patients with metastatic or advanced solid tumors, genomic testing using multigene genomic sequencing is preferred whenever patients are eligible for a genomic biomarker–linked therapy that a regulatory agency has approved (strength of recommendation: moderate).

- PCO 1.2.2. Multigene panel–based genomic testing should be used whenever more than one genomic biomarker is linked to a regulatory agency–approved therapy (strength of recommendation: strong).
- PCO 1.3. If the genomic sequencing results are used to inform clinical care, such testing must be performed in an appropriately certified laboratory (strength of recommendation: strong).
- PCO 1.4. Clinical decision making should incorporate (1) the known or predicted impact of a specific genomic alteration on protein expression or function and (2) clinical data on the efficacy of targeting that genomic alteration with a particular agent (strength of recommendation: strong)
- PCO 2.1. Mismatch repair deficiency status (dMMR) should be evaluated on patients with metastatic or advanced solid tumors who are candidates for immunotherapy. There are multiple approaches, including using large multigene panel–based testing to assess microsatellite instability (MSI). Consider the prevalence of dMMR and/or MSI-H status in individual tumor types when making this decision (strength of recommendation: strong).
- PCO 2.2. When TMB [tumor mutational burden] may influence the decision to use immunotherapy, testing should be performed with either large multigene panels with validated TMB testing or whole-exome analysis (strength of recommendation: strong).
- PCO 4.1. Genomic testing should be considered to determine candidacy for tumor-agnostic therapies in patients with metastatic or advanced solid tumors without approved genomic biomarker–linked therapies (strength of recommendation: moderate).<sup>2</sup>

### **National Comprehensive Cancer Network (NCCN)**

[NCCN Clinical Practice Guidelines in Oncology](#) are used to determine the medical necessity of NGS testing for cancer. For each request, the most up to date NCCN guideline will be reviewed.<sup>3</sup>

## **HEALTH EQUITY CONSIDERATIONS**

The Centers for Disease Control and Prevention (CDC) defines health equity as the state in which everyone has a fair and just opportunity to attain their highest level of health. Achieving health equity requires addressing health disparities and social determinants of health. A health disparity is the occurrence of diseases at greater levels among certain population groups more than among others. Health disparities are linked to social determinants of health which are non-medical factors that influence health outcomes such as the conditions in which people are born, grow, work, live, age, and the wider set of forces and systems shaping the conditions of daily life. Social determinants of health include unequal access to health care, lack of education, poverty, stigma, and racism.

The U.S. Department of Health and Human Services Office of Minority Health calls out unique areas where health disparities are noted based on race and ethnicity. Providence Health Plan (PHP) regularly reviews these areas of opportunity to see if any changes can be made to our medical or pharmacy policies to support our members obtaining their highest level of health. Upon review, PHP creates a

Coverage Recommendation (CORE) form detailing which groups are impacted by the disparity, the research surrounding the disparity, and recommendations from professional organizations. PHP Health Equity COREs are updated regularly and can be found online [here](#).

## BILLING GUIDELINES AND CODING

Some, but not all, panel tests may have a specific CPT or HCPCS code assigned (81410-81471). When no specific CPT or HCPCS code exists for the panel, the provider is required to bill using an unlisted code. It is not appropriate for the provider to bill any of the tests/genes in a panel separately as if they were performed individually. See [Coding Policy 30.0, Laboratory Panel Billing](#), for more information.

| CODES* |   |  |
|--------|---|--|
| 0022U  | Targeted genomic sequence analysis panel, non-small cell lung neoplasia, DNA and RNA analysis, 23 genes, interrogation for sequence variants and rearrangements, reported as presence/ or absence of variants and associated therapy(ies) to consider   | Oncomine Dx Target Test, <i>Life Technologies Corporation</i>  |
| 0334U  | Oncology (solid organ), targeted genomic sequence analysis, formalin-fixed paraffinembedded (FFPE) tumor tissue, DNA analysis, 84 or more genes, interrogation for sequence variants, gene copy number  | Guardant360 Tissue, <i>Guardant Health, Inc.</i>   |
| 0037U  | Targeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden  | FoundationOne CDx, <i>Foundation Medicine, Inc.</i>  |
| 0048U  | Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin-embedded tumor tissue, report of clinically significant mutation(s) | Memorial Sloan Kettering- Integrated Mutational Profiling of Actionable Cancer Targets (MSK-IMPACT), <i>Memorial Sloan Kettering</i> |
| 0209U  | Cytogenomic constitutional (genome-wide) analysis, interrogation of genomic regions for copy number, structural changes and areas of homozygosity for chromosomal abnormalities   | CNGnome, <i>PerkinElmer Genomics</i>   |
| 0211U  | Oncology (pan-tumor), DNA and RNA by next-generation sequencing, utilizing formalin-fixed paraffin-embedded tissue, interpretative report for single nucleotide variants, copy number alterations, tumor mutational burden, and microsatellite instability, with therapy association  | MI Tumor Seek, <i>Caris Life Sciences</i>  |
| 0244U  | Oncology (solid organ), DNA, comprehensive genomic profiling, 257 genes, interrogation for single-nucleotide variants, insertions/deletions, copy number alterations, gene rearrangements, tumor-mutational burden and microsatellite   | Oncotype MAP Pan Cancer Tissue Test, <i>Genomic Health, Inc.</i>   |

|       |  |   |
|-------|--|---|
|       | instability, utilizing formalin-fixed paraffin-embedded tumor tissue   |   |
| 0250U | Oncology (solid organ neoplasm), targeted genomic sequence DNA analysis of 505 genes, interrogation for somatic alterations (SNVs [single nucleotide variant], small insertions and deletions, one amplification, and four translocations), microsatellite instability and tumor-mutation burden | PGDx Elio Tissue Complete, <i>Personal Genome Diagnostics</i>                             |
| 0268U | Hematology (atypical hemolytic uremic syndrome [aHUS]), genomic sequence analysis of 15 genes, blood, buccal swab, or amniotic fluid   | Versiti aHUS Genetic Evaluation, <i>Versiti Diagnostic Laboratories</i>                   |
| 0269U | Hematology (autosomal dominant congenital thrombocytopenia), genomic sequence analysis of 22 genes, blood, buccal swab, or amniotic fluid  | Versiti Autosomal Dominant Thrombocytopenia Panel, <i>Versiti Diagnostic Laboratories</i> |
| 0270U | Hematology (congenital coagulation disorders), genomic sequence analysis of 20 genes, blood, buccal swab, or amniotic fluid  | Versiti Coagulation Disorder Panel, <i>Versiti Diagnostic Laboratories</i>                |
| 0272U | Hematology (genetic bleeding disorders), genomic sequence analysis of 60 genes and duplication/deletion of PLAUI, blood, buccal swab, or amniotic fluid, comprehensive   | Versiti Comprehensive Bleeding Disorder Panel, <i>Versiti Diagnostic Laboratories</i>     |
| 0273U | Hematology (genetic hyperfibrinolysis, delayed bleeding), genomic sequence analysis of 8 genes (F13A1, F13B, FGA, FGB, FGG, SERPINA1, SERPINE1, SERPINF2, PLAUI), blood, buccal swab, or amniotic fluid  | Versiti Fibrinolytic Disorder Panel, <i>Versiti Diagnostic Laboratories</i>               |
| 0274U | Hematology (genetic platelet disorders), genomic sequence analysis of 62 genes and duplication/deletion of PLAUI, blood, buccal swab, or amniotic fluid  | Comprehensive Platelet Disorder Panel, <i>Versiti Diagnostic Laboratories</i>             |
| 0276U | Hematology (inherited thrombocytopenia), genomic sequence analysis of 23 genes, blood, buccal swab, or amniotic fluid  | Versiti Inherited Thrombocytopenia Panel, <i>Versiti Diagnostic Laboratories</i>          |
| 0277U | Hematology (genetic platelet function disorder), genomic sequence analysis of 40 genes and duplication/deletion of PLAUI, blood, buccal swab, or amniotic fluid  | Versiti Platelet Function Disorder Panel, <i>Versiti Diagnostic Laboratories</i>          |



|                  |   |  |
|------------------|---|--|
| 0278U            | Hematology (genetic thrombosis), genomic sequence analysis of 14 genes, blood, buccal swab, or amniotic fluid   | Versiti Thrombosis Panel, <i>Versiti Diagnostic Laboratories</i>                   |
| 0313U            | Oncology (pancreas), DNA and mRNA next-generation sequencing analysis of 74 genes and analysis of CEA (CEACAM5) gene expression, pancreatic cyst fluid, algorithm reported as a categorical result (ie, negative, low probability of neoplasia or positive, high probability of neoplasia)  | PancreasSeq Genomic Classifier, <i>UPMC</i>  |
| 0329U            | Oncology (neoplasia), exome and transcriptome sequence analysis for sequence variants, gene copy number amplifications and deletions, gene rearrangements, microsatellite instability and tumor mutational burden utilizing DNA and RNA from tumor with DNA from normal blood or saliva for subtraction, report of clinically significant mutation(s) with therapy associations                 | Oncomap Xtra, <i>Genomic Health</i>  |
| 0379U            | Targeted genomic sequence analysis panel, solid organ neoplasm, DNA (523 genes) and RNA (55 genes) by next-generation sequencing, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability, and tumor mutational burden  | Solid Tumor Expanded Panel, <i>Quest Diagnostics</i>                               |
| 0391U            | Oncology (solid tumor), DNA and RNA by next-generation sequencing, utilizing formalin-fixed paraffin-embedded (FFPE) tissue, 437 genes, interpretive report for single nucleotide variants, splice site variants, insertions/deletions, copy number alterations, gene fusions, tumor mutational burden, and microsatellite instability, with algorithm quantifying immunotherapy response score | Strata Select. <i>Strata Oncology Inc</i>  |
| 0444U            | Oncology (solid organ neoplasia), targeted genomic sequence analysis panel of 361 genes, interrogation for gene fusions, translocations, or other rearrangements, using DNA from formalin-fixed paraffin-embedded (FFPE) tumor tissue, report of clinically significant variant(s)  | Aventa FusionPlus™, <i>Aventa Genomics, LLC</i>                                    |
| <del>0448U</del> | <b>Termed 12/31/2024</b><br><del>Oncology (lung and colon cancer), DNA, qualitative, next generation sequencing detection of single nucleotide variants and deletions in EGFR and KRAS genes, formalin-fixed paraffin embedded (FFPE) solid tumor samples, reported as presence or absence of targeted mutation(s), with recommended therapeutic options</del>                                  | <del>ONCO/Reveal™ DX Lung and Colon Cancer Assay, <i>Pillar® Biosciences</i></del> |
| 0471U            | Oncology (colorectal cancer), qualitative real-time PCR of 35 variants of KRAS and NRAS genes (exons 2, 3, 4), formalin-fixed paraffin-embedded (FFPE), predictive, identification of detected mutations  | CRCdx® RAS Mutation Detection Kit, <i>EntroGen, Inc.</i>                           |
| 0473U            | Oncology (solid tumor), next-generation sequencing (NGS) of DNA from formalin-fixed paraffin-embedded (FFPE) tissue with comparative sequence analysis from a matched normal specimen (blood or saliva), 648 genes, interrogation for   | xT CDx, <i>Tempus AI Inc.</i>  |

|       |  |  |
|-------|--|--|
|       | sequence variants, insertion and deletion alterations, copy number variants, rearrangements, microsatellite instability, and tumor-mutation burden   |  |
| 0478U | Oncology (non-small cell lung cancer), DNA and RNA, digital PCR analysis of 9 genes (EGFR, KRAS, BRAF, ALK, ROS1, RET, NTRK 1/2/3, ERBB2, and MET) in formalin-fixed paraffin-embedded (FFPE) tissue, interrogation for single-nucleotide variants, insertions/deletions, gene rearrangements, and reported as actionable dete                                 | Lung HDPCR™, Protean BioDiagnostics  |
| 0481U | IDH1 (isocitrate dehydrogenase 1 [NADP+]), IDH2 (isocitrate dehydrogenase 2 [NADP+]), and TERT (telomerase reverse transcriptase) promoter (eg, central nervous system [CNS] tumors), next-generation sequencing (single-nucleotide variants [SNV], deletions, and insertions)   | IDH1, IDH2, and TERT Mutation Analysis, Next-Generation Sequencing, Tumor, Mayo Clinic |
| 0498U | Oncology (colorectal), next-generation sequencing for mutation detection in 43 genes and methylation pattern in 45 genes, blood, and formalin-fixed paraffin-embedded (FFPE) tissue, report of variants and methylation pattern with interpretation  | OptiSeq™ Colorectal Cancer NGS Panel, DiaCarta, Inc                                    |
| 0499U | Oncology (colorectal and lung), DNA from formalin-fixed paraffin-embedded (FFPE) tissue, next-generation sequencing of 8 genes (NRAS, EGFR, CTNNB1, PIK3CA, APC, BRAF, KRAS, and TP53), mutation detection   | OptiSeq™ Dual Cancer Panel Kit, DiaCarta, Inc  |
| 0523U | Oncology (solid tumor), DNA, qualitative, next-generation sequencing (NGS) of single nucleotide variants (SNV) and insertion/deletions in 22 genes utilizing formalin-fixed paraffin-embedded tissue, reported as presence or absence of mutation(s), location of mutation(s), nucleotide change, and amino acid change  | oncoReveal™ CDx by Pillar Biosciences, Inc.  |
| 0538U | Oncology (solid tumor), next-generation targeted sequencing analysis, formalin-fixed paraffin-embedded (FFPE) tumor tissue, DNA analysis of 600 genes, interrogation for single-nucleotide variants, insertions/deletions, gene rearrangements, and copy number alterations, microsatellite instability, tumor mutation burden, reported as actionable variant | PredicineATLAS™ Assay, Predicine Inc.  |
| 0543U | Oncology (solid tumor), next-generation sequencing of DNA from formalin-fixed paraffin-embedded (FFPE) tissue of 517 genes, interrogation for single-nucleotide variants, multi-nucleotide variants, insertions and deletions from DNA, fusions in 24 genes and splice variants in 1 gene from RNA, and tumor mutation burden                                  | TruSight™ Oncology Comprehensive, Illumina, Inc  |
| 0592U | Oncology (hematolymphoid neoplasms), DNA, targeted genomic sequence of 417 genes, interrogation for gene fusions, translocations, rearrangements, utilizing formalin-fixed paraffin-embedded (FFPE) tumor tissue, results report clinically significant variant(s)   | Aventa Lymphoma, Aventa Genomics LLC   |

|       |   |  |
|-------|---|--|
| 81445 | Solid organ neoplasm, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants and copy number variants or rearrangements, if performed; DNA analysis or combined DNA and RNA analysis  |  |
| 81449 | Solid organ neoplasm, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants and copy number variants or rearrangements, if performed; RNA analysis   |  |
| 81451 | Hematolymphoid neoplasm or disorder, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA analysis  |  |
| 81455 | Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, genomic sequence analysis panel, interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; DNA analysis or combined DNA and RNA analysis  |  |
| 81456 | Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, genomic sequence analysis panel, interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA analysis   |  |
| 81457 | Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis, microsatellite instability  |  |
| 81458 | Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis, copy number variants and microsatellite instability   |  |
| 81459 | Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements  |  |
| 81524 | Oncology (central nervous system tumor), DNA methylation analysis of at least 10,000 methylation sites, utilizing DNA extracted from formalin-fixed tumor tissue, algorithm(s) reported as probability of matching a reference tumor family and class, and MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation status, if performed |  |
| 81479 | Unlisted Molecular Pathology  |  |

**\*Coding Notes:**

- The above code list is provided as a courtesy and may not be all-inclusive. Inclusion or omission of a code from this policy neither implies nor guarantees reimbursement or coverage. Some codes may not require routine review for medical necessity, but they are subject to provider contracts, as well as member benefits, eligibility and potential utilization audit.
- All unlisted codes are reviewed for medical necessity, correct coding, and pricing at the claim level. If an unlisted code is submitted for non-covered services addressed in this policy then it will be **denied as not covered**. If an unlisted

code is submitted for potentially covered services addressed in this policy, to avoid post-service denial, **prior authorization is recommended**.

- See the non-covered and prior authorization lists on the Company [Medical Policy, Reimbursement Policy, Pharmacy Policy and Provider Information website](#) for additional information.
- HCPCS/CPT code(s) may be subject to National Correct Coding Initiative (NCCI) procedure-to-procedure (PTP) bundling edits and daily maximum edits known as “medically unlikely edits” (MUEs) published by the Centers for Medicare and Medicaid Services (CMS). This policy does not take precedence over NCCI edits or MUEs. Please refer to the CMS website for coding guidelines and applicable code combinations.

## REFERENCES

1. Hayes. Comprehensive Molecular Profiling Test(s) for Solid Tumors Intended to be Used as Broad Molecular Profiling Tool to Assigned Matched Therapy. Published Jan 11, 2022. <https://evidence.hayesinc.com/report/pmi.pancancer5125>. Accessed 4/25/2025.
2. Chakravarty D, Johnson A, Sklar J, et al. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. *Journal of Clinical Oncology*. 2022;40(11):1231-1258.
3. National Comprehensive Cancer Network. NCCN Guideline. Treatment by cancer type. . [https://www.nccn.org/guidelines/category\\_1](https://www.nccn.org/guidelines/category_1). Accessed 4/25/2025.

## POLICY REVISION HISTORY

| DATE    | REVISION SUMMARY   |
|---------|--|
| 2/2023  | Converted to new policy template.                                      |
| 4/2023  | Q2 2023 Code set update  |
| 7/2023  | Q3 2023 Code set update  |
| 8/2023  | Annual update. Added CPT 0329U   |
| 10/2023 | Q4 Code set update. Revised code descriptions                          |
| 1/2024  | Q1 2024 code set update. 3 new codes and 4 code description revisions. |
| 4/2024  | Q2 2024 code set update. 2 new codes.                                  |
| 6/2024  | Annual review. Tests added to examples of NGS testing resources.       |
| 7/2024  | Q3 2024 code set update. 1 new code added.                             |
| 10/2024 | Q4 2024 code set update. Codes added.                                  |
| 1/2025  | Q1 2025 code set update.   |
| 4/2025  | Q2 2025 code set update.   |
| 6/2025  | Annual update. No changes to criteria.                                 |
| 10/2025 | Q4 2025 code set update. 1 code added.                                 |
| 1/2026  | Q1 2026 code set update.   |